Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
PLx Pharma Winddown Corp. (PLXP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results|
Docs:
|
"PLx Pharma Inc. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, 2021 December 31, 2020 ASSETS CURRENT ASSETS Cash and cash equivalents $ 82,554,297 $ 22,448,651 Accounts receivable, net 3,253,312 - Inventory 2,190,350 143,380 Prepaid expenses and other current assets 616,249 393,470 TOTAL CURRENT ASSETS 88,614,208 22,985,501 NON-CURRENT ASSETS Property and equipment, net 888,658 1,225,879 Right of use assets 255,121 327,161 Goodwill 2,061,022 2,061,022 Security deposit 17,036 17,036 TOTAL ASSETS $ 91,836,045 $ 26,616,599 LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 6,452,172 $ 862,568 Accrued bonuses 839,701 1,184,823 Accrued interest - 597,411 Term loan, net of discount and fees -..." |
|
| 11/16/2020 |
8-K
| Quarterly results|
Docs:
|
"The approval of an advisory vote on the frequency of the advisory vote on the compensation of our named executive officers; and",
"The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’ s 2021 annual meeting of stockholders and until their successors are duly elected and qualify;",
"The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’ s 2021 annual meeting of stockholders and until their successors are duly elected and qualify;",
"The election of each of Gary Balkema, Kirk Calhoun, Robert Casale, John Hadden II, Michael Valentino and Natasha Giordano to serve as directors until the Company’ s 2021 annual meeting of stockholders and until their successors are duly elected and qualify;",
"PLx Pharma Inc. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2020 2019 ASSETS CURRENT ASSETS Cash and cash equivalents $ 9,086,525 $ 14,001,304 Accounts receivable — 18,683 Inventory, net 143,380 — Prepaid expenses and other current assets 387,801 263,268 TOTAL CURRENT ASSETS 9,617,706 14,283,255 NON-CURRENT ASSETS Property and equipment, net 1,252,434 1,466,646 Right of use assets 402,640 618,158 Goodwill 2,061,022 2,061,022 Security deposit 17,035 73,665 TOTAL ASSETS $ 13,350,837 $ 18,502,746 LIABILITIES, SERIES A AND SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 612,367 $ 928,921 Accrued bonuses 718,092 1,166,821 Accrued interest 589,840 34,964 Current portion of term loan, net of discount...",
"PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration -- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 – Sparta, New Jersey, November 16, 2020 — PLx Pharma Inc. , a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, announced today that two chemistry and manufacturing control supplemental New Drug Applications , one for VAZALORE 325 mg and one for VAZALORE 81 mg dose , were submitted to the U.S. Food and Drug Administration in October for regulatory approval. The 325 mg sNDA provided information on..." |
|
| 08/14/2020 |
8-K
| Quarterly results |
| 05/15/2020 |
8-K
| Quarterly results |
| 03/13/2020 |
8-K
| Quarterly results |
| 11/08/2019 |
8-K
| Quarterly results |
| 03/08/2019 |
8-K
| Quarterly results |
|
|